Characterization of C3dg binding to a recess formed between short consensus repeats 1 and 2 of complement receptor type 2 (CR2; CD21)

Journal of Immunology

Volumn 161, Issue 9, 1998, Pages 4604-4610

  Prodinger, Wolfgang M ^a   Schwendinger, Michael G ^a   Schoch, Jürgen ^a   Köchle, Maria ^a   Larcher, Clara ^a   Dierich, Manfred P ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3D; COMPLEMENT RECEPTOR; IMMUNOGLOBULIN G1; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANTIGEN BINDING; ARTICLE; B LYMPHOCYTE; BINDING COMPETITION; CONTROLLED STUDY; EPSTEIN BARR VIRUS; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; RECEPTOR BINDING; VIRUS INFECTION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGEN-ANTIBODY REACTIONS; BINDING SITES; BINDING, COMPETITIVE; COMPLEMENT C3B; COMPUTER SIMULATION; CONSENSUS SEQUENCE; EPITOPES; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; HYBRIDOMAS; MICE; MICE, INBRED BALB C; MICROSPHERES; MODELS, IMMUNOLOGICAL; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PEPTIDE LIBRARY; PROTEIN BINDING; PROTEIN CONFORMATION; RECEPTORS, COMPLEMENT 3D; REPETITIVE SEQUENCES, AMINO ACID; SOLUBILITY;

EID: 0032211058     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Tedder, T. F., L. T. Clement, and M. D. Cooper. 1984. Expression of C3d receptors during human B cell differentiation: immunofluorescence analysis with the HB-5 monoclonal antibody. J. Immunol. 133:678.
2. Reynes, M., J. P. Aubert, J. H. Cohen, J. Audouin, V. Tricottet, J. Diebold, and M. D. Kazatchkine. 1985. Human follicular dendritic cells express CR1, CR2, and CR3 complement receptor antigens. J. Immunol. 135:2687.
3. Fischer, E., C. Delibrias, and M. D. Kazatchkine. 1991. Expression of CR2 (the C3dg/EBV receptor, CD21) on normal human peripheral blood T lymphocytes. J. Immunol. 146:865.
4. Tsoukas, C. D., and J. D. Lambris. 1988. Expression of CR2/EBV receptors on human thymocytes detected by monoclonal antibodies. Eur. J. Immunol. 18:1299.
5. Casque, P., P. Chan, C. Mauger, M. T. Schouft, S. Singhrao, M. P. Dierich, B. P. Morgan, and M. Fontaine. 1996. Identification and characterization of complement C3 receptors on human astrocytes. J. Immunol. 156:2247.
6. Fearon, D. T., and R. H. Carter. 1995. The CD19/CR2/TAPA-1 complex of B lymphocytes: linking natural to acquired immunity. Annu. Rev. Immunol. 13:127.
7. Matsumoto, A. K., J. Kopicky Burd, R. H. Carter, D. A. Tuveson, T. F. Tedder, and D. T. Fearon. 1991. Intersection of the complement and immune systems: a signal transduction complex of the B lymphocyte-containing complement receptor type 2 and CD19. J. Exp. Med. 173:55.
8. Carter, R. H., and D. T. Fearon. 1992. CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science 256:105.
9. Dempsey, P. W., M. E. D. Allison, S. Akkaraju, C. C. Goodnow, and D. T. Fearon. 1996. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 271:348.
10. Nemerow, G. R., R. A. Houghten, M. D. Moore, and N. R. Cooper. 1989. Identification of an epitope in the major envelope protein of Epstein-Barr virus that mediates viral binding to the B lymphocyte EBV receptor (CR2). Cell 56:369.
11. Lowell, C. A., L. B. Klickstein, R. H. Carter, J. A. Mitchell, D. T. Fearon, and J. M. Ahearn. 1989. Mapping of the Epstein-Barr virus and C3dg binding sites to a common domain on complement receptor type 2. J. Exp. Med. 170:1931.
12. Aubry, J. P., S. Pochon, J. F. Gauchat, A. Nueda Marin, V. M. Holers, P. Graber, C. Siegfried, and J. Y. Bonnefoy. 1994. CD23 interacts with a new functional extracytoplasmic domain involving N-linked oligosaccharides on CD21. J. Immunol. 152:5806.
13. Henchoz, S., J. F. Gauchat, J. P. Aubry, P. Graber, S. Pochon, and J. Y. Bonnefoy. 1994. Stimulation of human IgE production by a subset of anti-CD21 monoclonal antibodies: requirement of a co-signal to modulate epsilon transcripts. Immunology 81:285.
14. Bonnefoy, J. Y., S. Henchoz, D. Hardie, M. J. Holder, and J. Gordon. 1993. A subset of anti-CD21 antibodies promote the rescue of germinal center B cells from apoptosis. Eur. J. Immunol. 23:969.
15. Reid, K. B. M., and A. J. Day. 1989. Structure-function relationship of the complement components, Immunol. Today 10:177.
16. Barlow, P. N., M. Baron, D. G. Norman, A. J. Day, A. C. Willis, R. B. Sim, and I. D. Campbell. 1991. Secondary structure of a complement control protein module by two-dimensional 1H NMR. Biochemistry 30:997.
17. Barlow, P. N., A. Steinkasserer, D. G. Norman, B. Kieffer, A. P. Wiles, R. B. Sim, and I. D. Campbell. 1993. Solution structure of a pair of complement modules by nuclear magnetic resonance. J. Mol. Biol. 232:268.
18. Norman, D. G., P. N. Barlow, M. Baron, A. J. Day, R. B. Sim, and I. D. Campbell. 1991. Three-dimensional structure of a complement control protein module in solution. J. Mol. Biol. 219:717.
19. Rao, P. E., S. D. Wright, E. F. Westberg, and G. Goldstein. 1985. OKB7, a monoclonal antibody that reacts at or near the C3d binding site of human CR2. Cell. Immunol. 93:549.
20. Nemerow, G. R., R. Wolfert, M. E. McNaughton, and N. R. Cooper. 1985. Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2). J. Virol. 55:347.
21. Nemerow, G. R., M. E. McNaughton, and N. R. Cooper. 1985. Binding of monoclonal antibody to the Epstein Barr virus (EBV)/CR2 receptor induces activation and differentiation of human B lymphocytes. J. Immunol. 135:3068.
22. Bohnsack, J. F., and N. R. Cooper. 1988. CR2 ligands modulate human B cell activation. J. Immunol. 141:2569.
23. Luxembourg, A. T., and N. R. Cooper. 1994. Modulation of signaling via the B cell antigen receptor by CD21, the receptor for C3dg and EBV. J. Immunol. 153:4448.
24. Griffioen, A. W., S. W. Franklin, B. J. Zegers. and G. T. Rijkers. 1993. Expression and functional characteristics of the complement receptor type 2 on adult and neonatal B lymphocytes. Clin. Immunol. Immunopathol. 69:1.
25. Delibrias, C. C., E. Fischer, G. Bismuth, and M. D. Kazatchkine. 1992. Expression, molecular association, and functions of C3 complement receptors CR1 (CD35) and CR2 (CD21) on the human T cell line HPB-ALL. J. Immunol. 149: 768.
26. Carter, R. H., and D. T. Fearon. 1989. Polymeric C3dg primes human B lymphocytes for proliferation induced by anti-IgM. J. Immunol. 143:1755.
27. Reljic, R., G. Cosentino, and H. J. Gould. 1997. Function of CD23 in the response of human B cells to antigen. Eur. J. Immunol. 27:572.
28. Molina, H., S. J. Perkins, J. Guthridge, J. Gorka, T. Kinoshita, and V. M. Holers. 1995. Characterization of a complement receptor 2 (CR2, CD21) ligand binding site for C3: an initial model of ligand interaction with two linked short consensus repeat modules. J. Immunol. 154:5426.
29. Kinoshita, T., G. Thyphronitis, G. C. Tsokos, F. D. Finkelman, K. Hong, H. Sakai, and K. Inoue. 1990. Characterization of murine complement receptor type 2 and its immunological cross-reactivity with type 1 receptor. Int. Immunol. 2:651.
30. Pramoonjago, P., J. Takeda, Y. U. Kim, K. Inoue, and T. Kinoshita. 1993. Ligand specificities of mouse complement receptor types I (CR1) and 2 (CR2) purified from spleen cells. Int. Immunol. 5:337.
31. Martin, D. R., A. Yuryev, K. R. Kall, D. T. Fearon, and J. M. Ahearn. 1991. Determination of the structural basis for selective binding of Epstein-Barr virus to human complement receptor type 2. J. Exp. Med. 174:1299.
32. Martin, D. R., R. L. Marlowe, and J. M. Ahearn. 1994. Determination of the role for CD21 during Epstein-Barr virus infection of B-lymphoblastoid cells. J. Virol. 68:4716.
33. Schwendinger, M. G., M. Spruth, J. Schoch, M. P. Dierich, and W. M. Prodinger. 1997. A novel mechanism of alternative pathway complement activation accounts for the deposition of C3-fragments on CR2-expressing homologous cells. J. Immunol. 158:5455.
34. Prodinger, W. M., J. Schoch, M. G. Schwendinger, J. Hellwage, W. Parson, P. F. Zipfel, and M. P. Dierich. 1997. Expression in insect cells of the functional domain of CD21 (complement receptor type two) as a truncated soluble molecule using a baculovirus vector. Immunopharmacology 38:141.
35. Hoffman, G. J., S. G. Lazarowitz, and S. D. Hayward. 1980. Monoclonal antibody against a 250,000-dalton glycoprotein of a Epsrein-Barr virus identifies a membrane antigen and a neutralizing antigen. Proc. Natl. Acad. Sci. USA 77:2979.
36. Berger, P., W. Panmoung, D. Khaschabi, B. Mayregger, and G. Wick. 1988. Antigenic features of human follicle stimulating hormone delineated by monoclonal antibodies and construction of an immunoradiometric assay. Endocrinology 123:2351.
37. Prodinger, W. M., J. Hellwage, M. Spruth, M. P. Dierich, and P. F. Zipfel. 1998. The C-terminus of factor H: monoclonal antibodies inhibit heparin binding and identify epitopes common to factor H and factor H-related protein. Biochem. J. 331:41.
38. Miller, G., and M. Lipman. 1972. Release of infectious Epstein-Barr virus by transformed marmoset leukocytes. Proc. Natl. Acad. Sci. USA 70:190.
39. Nemerow, G. R., and N. R. Cooper. 1981. Isolation of Epstein-Barr virus and studies of its neutralization by human IgG and complement. J. Immunol. 127:272.
40. Kearney, J. F., A. Radbruch, B. Liesegang, and K. Rajewsky. 1979. A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines. J. Immunol. 123:1548.
41. Fazekas de St. Groth, S., and D. Scheidegger. 1980. Production of monoclonal antibodies: strategy and tactics. J. Immunol. Methods 35:1.
42. Prodinger, W. M., C. Larcher, M. Schwendinger, and M. P. Dierich. 1996. Ligation of the functional domain of complement receptor type 2 (CR2, CD21) is relevant for complex formation in T cell lines. J. Immunol. 156:2580.
43. Janatova, J. 1988. C3, C5 components and C3a, C4a, and C5a fragments of the complement system. Methods Enzymol. 162:579.
44. Vik, D. P., and D. T. Fearon. 1985. Neutrophils express a receptor for iC3b, C3dg, and C3d that is distinct from CR1, CR2, and CR3. J. Immunol. 134:2571.
45. Weis, J. J., L. E. Toothaker, J. A. Smith, J. H. Weis, and D. T. Fearon. 1988. Structure of the human B lymphocyte receptor for C3d and the Epstein-Barr virus and relatedness to other members of the family of C3/C4 binding proteins. J. Exp. Med. 167:1047.
46. Frank, R. 1992. SPOT synthesis: an easy technique for the positionally addressable, parallel chemical synthesis on a membrane support. Tetrahedron 48:9217.
47. Paccaud, J. P., J. L. Carpentier, and J. A. Schifferli. 1988. Direct evidence for the clustered nature of complement receptors type 1 on the erythrocyte membrane. J. Immunol. 141:3889.
48. Moore, M. D., R. G. DiScipio, N. R. Cooper, and G. R. Nemerow. 1989. Hydrodynamic, electron microscopic, and ligand-binding analysis of the Epstein-Barr virus/C3dg receptor (CR2). J. Biol. Chem. 264:20576.
49. Wilson, B. S., J. L. Platt, and N. E. Kay. 1985. Monoclonal antibodies to the 140.000 mol wt glycoprotein of B lymphocyte membranes (CR2 receptor) initiates proliferation of B cells in vitro. Blood 66:824.
50. Molina, H., C. Brenner, S. Jacobi, J. Gorka, J. C. Carel, T. Kinoshita, and V. M. Holers. 1991. Analysis of Epstein-Barr virus-binding sites on complement receptor 2 (CR2/CD21) using human-mouse chimeras and peptides: at least two distinct sites are necessary for ligand-receptor interaction. J. Biol. Chem. 266: 12173.